medigraphic.com

2014, Número 1

<< Anterior Siguiente >>

Rev Hosp Jua Mex 2014; 81 (1)


Resistencia a la insulina, síndrome metabólico, diabetes mellitus y carcinogénesis mamaria

Vargas-Hernández VM, Vargas-Aguilar VM, Moreno-Eutimio MA, Acosta-Altamirano G, Flores-Barrios K, Tovar-Rodríguez JM

Idioma: Español
Referencias bibliográficas: 53
Paginas: 37-49
Archivo PDF: 273.11 Kb.


RESUMEN

El cáncer de mama (CM) es una enfermedad heterogénea y progresiva, actualmente se clasifica de acuerdo con su patrón de expresión genética: luminal A, luminal B, tipo basal y HER-2neu + y triple-negativo; 75 a 80% tienen receptores hormonales positivos, 15 a 20% son positivos para HER-2neu y 10 a 20% son triples negativos, con receptores hormonales y HER2-neu negativos; el diagnóstico se realiza por exclusión, el síndrome metabólico se relaciona con mayor incidencia de estos cánceres, donde el eje insulina-leptina-adiponectina está implicado en su carcinogénesis.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Sasa M, Bando Y, Takahashi M, Hirose T, Nagao T. Screening for basal marker expression is necessary for decision of therapeutic strategy for triple-negative breast cancer. J Surg Oncol 2008; 97(1): 30-34.

  2. Martinez E, Magro A, Chirivella I, Lluch A. Cáncer mamario basal-like. En: Vargas-Hernández VM (ed.). Cáncer en la Mujer. México: Alfil; 2011, p. 1907-1919.

  3. Cheang MCU, Voduc D, Bajdik C, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clinic Cancer Research 2008; 14(5): 1368-1376.

  4. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a populationbased study from the California Cancer Registry. Cancer 2007; 109(9): 1721-1728.

  5. Morris GJ, Naidu S, Topham AK, et al. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the national cancer institute’s surveillance, epidemiology, and end results database. Cancer 2007; 110(4): 876-884.

  6. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006; 295(21): 2492-2502.

  7. Quirós AJL, Jimenez RY, Jimenez ME, Monge VM, Salazar SL. Carcinomas invasores triples negativos de la glándula mamaria: incidencia y características clínico-patológicas. Acta Med Costarric 2010; 52(2): 90-95.

  8. Currie CJ, Poole CD, Jenkins-Jones S, Gale EA, Johnson JA, Morgan CL. Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. Diabetes Care 2012; 35(2): 299-304.

  9. Brenton JD, Carey LA, Ahmed A, Caldas C. Molecular classification and molecular forecasting of breast cancer: ready for clinical application. J Clin Oncol 2005; 23(29): 7350-7360.

  10. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Bodymass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008; 371(9612): 569-578.

  11. Harvie M, Hooper L, Howell AH. Central obesity and breast cancer risk: a systematic review. Obesity Rev 2003; 4(3): 157-173.

  12. Larsson SC, Mantzoros CS, Wolk A. Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer 2007; 121(479): 856-862.

  13. Maiti B, Kundranda MN, Spiro TP, Daw HA. The association of metabolic syndrome with triple-negative breast cancer. Breast Cancer Research Treat 2010; 121(2): 479-483.

  14. Kitahara CM, De González AB, Freedman ND, et al. Total cholesterol and cancer risk in a large prospective study in Korea. J Clin Oncol 2011; 29(12): 1592-1598.

  15. Peeters PHM, Van Noord PAH, Hoes AW, Fracheboud J, Gimbrère CHF, Grobbee DE. Hypertension and breast cancer risk in a 19-year follow-up study (the DOM cohort). Diagnostic investigation into mammarian cancer. J Hypertension 2000; 18(3): 249-254.

  16. Vargas HVM, Vargas AVM, Acosta AG, Miranda FP, Moctezuma EJ. Estudio y manejo de la obesidad en mujeres y su riesgo oncológico. En: Vargas-Hernández VM (ed). Cáncer en la Mujer. México: Alfil; 2011, p. 1907-1919.

  17. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. Adults. N Engl J Med 2003; 348(17): 1625-1638.

  18. Ewertz M, Jensen MB, Gunnarsdóttir KA, et al. Effect of obesity on prognosis after early-stage breast cancer. J Clin Oncol 2011; 29(1): 25-31.

  19. Ademuyiwa FO, Groman A, O’Connor T, et al. Impact of body mass index on clinical outcomes in triple-negative breast cancer. Cancer 2011; 117(18): 4132-4140.

  20. Litton JK, Gonzalez-Angulo AM, Warneke CL, et al. Relationship between obesity and pathologic response to neoadjuvant chemotherapy among women with operable breast cancer. J Clin Oncol 2008; 26(25): 4072-4077.

  21. Melhem-Bertrandt A, Chavez-MacGregor M, Lei X, et al. Betablocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol 2011; 29(19): 2645-2652.

  22. Pierce JP, Stefanick ML, Flatt SW, et al. Greater survival after breast cancer in physically active women with high vegetable fruit intake regardless of obesity. J Clin Oncol 2007; 25(17): 2345-2351.

  23. Holmes MD, Chen WY, Feskanich D, Kroenke CH, Colditz GA. Physical activity and survival after breast cancer diagnosis. JAMA 2005; 293(20): 2479-2486.

  24. Abrahamson PE, Gammon MD, Lund MJ, et al. Recreational physical activity and survival among young women with breast cancer. Cancer 2006; 107(8): 1777-1785.

  25. Irwin ML, Smith AW, McTiernan A, et al. Influence of pre- and postdiagnosis physical activity on mortality in breast cancer survivors: the health, eating, activity, and lifestyle study. J Clin Oncol 2008; 26(24): 3958-3964.

  26. Enger SM, Bernstein L. Exercise activity, body size and premenopausal breast cancer survival. British J Cancer 2004; 90(11): 2138-2141.

  27. Chlebowski RT, Blackburn GL, Thomson CA, et al. Dietary fat reduction and breast cancer outcome: interim efficacy results from the women’s intervention nutrition study. J Nat Cancer Inst 2006; 98(24): 1767-1776.

  28. Pierce JP, Natarajan L, Caan BJ, et al. Influence of a diet very high in vegetables, fruit, and fiber and low in fat on prognosis following treatment for breast cancer: the women’s healthy eating and living (WHEL) randomized trial. JAMA 2007; 298(3): 289-298.

  29. Kwan ML, Kushi LH, Weltzien E, et al. Alcohol consumption and breast cancer recurrence and survival among women with early-stage breast cancer: the life after cancer epidemiology study. J Clin Oncol 2010; 28(29): 4410-4416.

  30. Kabat GC, Kim M, Caan BJ, et al. Repeated measures of serum glucose and insulin in relation to postmenopausal breast cancer. Int J Cancer 2009; 125(11): 2704-2710.

  31. Duggan C, Irwin ML, Xiao L, et al. Associations of insulin resistance and adiponectin with mortality in women with breast cancer. J Clin Oncol 2011; 29(1): 32-39.

  32. Irwin ML, Duggan C, Wang CY, et al. Fasting C-peptide levels and death resulting from all causes and breast cancer: the health, eating, activity, and lifestyle study. J Clin Oncol 2011; 29(1): 47-53.

  33. Erickson K, Patterson RE, Flatt SW, et al. Clinically defined type 2 diabetes mellitus and prognosis in early-stage breast cancer. J Clin Oncol 2011; 29(1): 54-60.

  34. Shimizu C, Hasegawa T, Tani Y, et al. Expression of insulin-like growth factor 1 receptor in primary breast cancer: immunohistochemical analysis. Hum Pathol 2004; 35(12): 1537-1542.

  35. Davison Z, De Blacquière GE, Westley BR, May FEB. Insulin-like growth factor-dependent proliferation and survival of triple-negative breast cancer cells: implications for therapy. Neoplasia 2011; 13(6): 504-515.

  36. Gonzalez-Chavez A. Diabetes y cáncer. En: Vargas- Hernández VM (ed.). Cáncer en la Mujer. México: Alfil; 2011, p. 857-862.

  37. Evans JMM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. Br Med J 2005; 330(7503): 1304-1305.

  38. Suissa S, Azoulay L, Dell’aniello S, Evans M, Vora J, Pollak M. Long-term effects of insulin glargine on the risk of breast cancer. Diabetologia 2011; 54(9): 2254– 2462.

  39. Liu B, Fan Z, Edgerton SM, et al. Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle 2009; 8(13): 2031-2040.

  40. Alimova IN, Liu B, Fan Z, et al. Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle 2009; 8(6): 909-915.

  41. Chlebowksi RT, McTiernan A, Fan Z, et al. Metformin and breast cancer incidence in postmenopausal diabetic women in the Women’s Health Initiative (WHI). J Clin Oncol 2011; 29(15): supplement, abstract 1503.

  42. Moschos S, Chan JL, Mantzoros CS. Leptin and reproduction: a review. Ferti Steril 2002; 77(3): 433-444.

  43. Jardé T, Perrier S, Vasson MP, Caldefie-Chézet F. Molecular mechanisms of leptin and adiponectin in breast cancer. Eur J Cancer 2011; 47(1): 33-43.

  44. Burga LN, Hu H, Juvekar A, et al. Loss of BRCA1 leads to an increase in epidermal growth factor receptor expression in mammary epithelial cells, and epidermal growth factor receptor-inhibition prevents estrogen receptor- negative cancers in BRCA1-mutant mice. Breast Cancer Research 2011; 13(2): R30.

  45. Otvos L Jr, Kovalszky I, Riolfi M, et al. Efficacy of a leptin receptor antagonist peptide in a mouse model of triplenegative breast cancer. Eur J Cancer 2011; 47(10): 1578- 1584.

  46. Nechushtan H, Steinberg H, Peretz T. Preliminary results of a phaseI/II of a combination of cetuximab and taxane for triple negative breast cancer patients. J Clin Onco 2009; 27(Suppl. 15): e12018.

  47. Körner A, Pazaitou-Panayiotou K, Kelesidis T, et al. Total and high-molecular-weight adiponectin in breast cancer: in vitro and in vivo studies. J Clin Endocrinol Metab 2007; 92(3): 1041-1048.

  48. Oh SW, Park CY, Lee ES, et al. Adipokines, insulin resistance, metabolic syndrome, and breast cancer recurrence: a cohort study. Breast Cancer Research 2011; 13(2): R34.

  49. Ouchi N, Shibata R, Walsh K. AMP-activated protein kinase signaling stimulates VEGF expression and angiogenesis in skeletal muscle. Circulation Research 2005; 96(8): 38-46.

  50. Van der Veldt AA, Lubberink M, Bahce I, Walraven M, de Boer MP, Greuter HN, et al. Rapid decrease in delivery of chemotherapy to tumors after anti-vegf therapy: implications for scheduling of anti-angiogenic drugs. Cancer Cell 2012; 21(1): 82-91.

  51. Macis D, Gandini S, Guerrieri GA, Johansson H, Magni P, Ruscica M, et al. Prognostic effect of circulating adiponectin in a randomized 2x2 trial of low-dose tamoxifen and fenretinide in premopausal women at risk for breast cancer. J Clin Oncol 2011; 30: 151-157.

  52. Fabian CJ. Adiponectin: A risk biomarker and attractive target for chemoprevention. J Clin Oncol 2011; 30: 124-126.

  53. Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Taylor SK, Hood N. Insulin and Obesity-Related Variables in Early-Stage Breast Cancer: Correlations and Time Course of Prognostic Associations. J Clin Oncol 2011; 30: 164-171.




2020     |     www.medigraphic.com